石杉碱甲联合脑蛋白水解物针剂治疗 血管性痴呆的临床疗效观察

韩菲  杨飏 李志云  代碧芬  鲍天昊^△

（昆明医科大学附属精神卫生中心，云南  昆明，650500）

中图分类号：R277.7    文献标识码：A    文章编号：1674-7860（2016）12-0039-03    证型：BDG

【摘  要】目的：探讨石杉碱甲联合脑蛋白水解物针剂治疗血管性痴呆临床疗效。方法：选取我院老年精神病科诊断为轻、中度血管性痴呆（VD）患者60例，随机分为两组，每组30例。对照组给予口服石杉碱甲共4周，治疗组在对照组基础上静滴脑蛋白水解物针剂2周（1个疗程），治疗4周后观察两组的临床疗效，按长谷川痴呆量表（HDS）和日常生活能力评定量表（ADL）的评分标准对患者认知功能及日常生活能力进行评分，疗效判定标准采用临床总体印象量表（CGI）评定。结果：治疗组的总有效率为93.3%，显著高于对照组的76.7%（P＜0.05）。ADL评分明显低于同组治疗前及对照组治疗后（P＜0.01）；HDS-R评分治疗后均高于治疗前，且治疗组HDS-R评分较对照组上升更明显（P＜0.01）。结论：石杉碱甲联合脑蛋白水解物针剂可更有效地改善轻、中度老年血管性痴呆患者的认知功能及生活能力，优于单用石杉碱甲。

【关键词】血管性痴呆；石杉碱甲；脑蛋白水解物；认知功能

【Abstract】Objective：Toinvestigate the clinical effect of Huperzine A combined with cerebroproteinhydrolysate injection in treating vascular dementia. Methods:60 cases of patients with mild andmoderate vascular dementia (VD) in our hospital were randomly divided into twogroups, with 30 cases in each group. The control group was given oral huperzineA for a total of 4 weeks while the treatment group received Huperzine Acombined with cerebroprotein hydrolysate injection for 2 weeks. The clinicalefficacy of the two groups was observed 4 weeks after the treatment, the patientsrecognize function and daily life ability score were evaluated by applying HasegawaDementia Scale (HDS) and activities of daily living rating scale (ADL), clinicalcriteria was made by using the Clinical Global Impression Scale (CGI). Results:The total effective rate of the treatment group was 93.3%, which wassignificantly higher than that of the control group of 76.7%, P<0.05. ADL score of the treatmentgroup was significantly lower than that of the same group before treatment and thatof the control group, P<0.01;HDS-R score after treatment was higher than that before treatment, and theimprovement of HDS-R score of the treatment group increased more significantly thanthat of the control group, P<0.01.Conclusion: Huperzine A combined withcerebroprotein hydrolysate injection could improve the recognize function anddaily life ability of patients with mild and moderate vascular dementiaeffectively, its effect was better than that of the single application of HuperzineA.

【Keywords】Vascular dementia; Huperzine A; Cerebroproteinhydrolysate; Cognitive function

doi:10.3969/j.issn.1674-7860.2016.12.019

参考文献：

[1]王立存,张玉莲,冯新义,等.血管性痴呆研究进展[J].疑难病杂志,2005(06):373-378.

[2]张蓓,吴海琴,张海雄.血管性痴呆的神经生化机制[J].国外医学(脑血管疾病分册),2005(09):672-675.

[3]亢相逢,李志洁,王艺,等.神经营养药物治疗早产儿脑损伤的临床疗效[J]. 中国实用神经疾病杂志,2013(01):60-61.

[4]许志强,张猛,李静,等.石杉碱甲治疗血管性痴呆的临床研究[J].中国临床神经科学,2009(02):163-165.

[5]奉红波.脑蛋白水解物与鼠神经生长因子对青光眼术后视神经的保护作用[J].眼科新进展,2014(05):477-479.

[6]魏婧,马玉玲,邵晓彤,等.脑蛋白水解物对小鼠记忆巩固能力的影响及机制[J].中国老年学杂志,2015(09):2362-2365.

[7]周永春.注射用脑蛋白水解物致过敏性休克1例[J].中国药师,2013(01):124.

[8]吴健,高家荣,李颖,等.脑蛋白水解物致高热、意识障碍1例[J].中国药物警戒,2012(12):768.

[9]王鲁宁,朱明伟,桂秋萍,等.383例老年人尸检资料中痴呆的病因分析[J]. 中华内科杂志,2003(11):40-43.

[10]徐红冰,王晓平,刘皋林.石杉碱甲的药理研究及临床应用[J].世界临床药物,2014(01):60-63.

[11]钱李冕,蒋丽丹.脑蛋白水解物治疗缺血性脑血管病的临床疗效及对神经功能的影响[J].实用药物与临床,2014(09):1123-1126.

[12]闫文学.多奈哌齐联合脑蛋白水解物治疗血管性痴呆的效果分析[J].中国实用神经疾病杂志,2015(19):103-105.

请点击此处【在线阅读全文PDF格式】

详情可登录【万方数据】

也可登录【中国知网】